Skip to content
Advertisement

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs
NOW ANOTHER COMPANY IS SOUNDING THE ALARM. HOW LONG DOES THIS TAKE? FIVE INVESTIGATES BRITTANY JOHNSON FIRST REPORTED ON THIS GROWING ISSUE LAST MONTH, SHOWING HOW SHE WAS ABLE TO ORDER COMPOUNDED SEMAGLUTIDE FROM TWO ONLINE COMPANIES. THAT’S THE MAIN INGREDIENT IN WEGOVY AND OZEMPIC. SHE FILLED OUT A MEDICAL INTAKE FORM BUT NEVER MET WITH A DOCTOR BEFORE THE INJECTIONS ARRIVED. NOW, THE COMPANY BEHIND TWO OTHER SIMILAR DRUGS IS RAISING MORE RED FLAGS ABOUT PEOPLE TRYING TO BUY VERSIONS OF MANJARO AND ZEP, FOUND ONLINE OR ON SOCIAL MEDIA. THE ACTIVE INGREDIENT IN THESE MEDICATIONS IS SOMETHING CALLED TIRZEPATIDE. IN AN OPEN LETTER ELI LILLY WROTE IN PART THAT THEY ARE, QUOTE, THE ONLY LAWFUL SUPPLIER OF FDA APPROVED TIRZEPATIDE MEDICINES AND THAT THEY DO NOT PROVIDE THAT INGREDIENT TO COMPOUNDING PHARMACIES, MED SPA WELLNESS CENTERS, ONLINE RETAILERS OR OTHER MANUFACTURERS. THEY ALSO PROVIDED PHOTOS OF WHAT REAL INJECTIONS OF MANJARO AND ZEPPELIN LOOK LIKE. DOCTOR FATIMA CODY STANFORD IS AN OBESITY EXPERT AT MASS GENERAL HOSPITAL. SHE SAYS THE RISKS OF TAKING COPYCAT FORMS OF THESE DRUGS ARE CLEAR. WHAT I WANT TO GIVE THEM IS SOMETHING THAT’S TESTED, SOMETHING THAT’S VALIDATED, AND WHEN WE’RE GIVING PATIENTS COMPOUNDED MEDICATION DEVENS I HAVE NO STUDY RESULTS TO BACK THEM. WHERE’S THE DATA? STANFORD SAYS SHE UNDERSTANDS THE URGENCY PEOPLE FEEL WHEN IT COMES TO GETTING THESE MEDICATIONS, BUT OFFERS THIS WARNING GO AND WORK WITH A HEALTH PROFESSIONAL, A DOCTOR THAT REALLY UNDERSTANDS THIS DISEASE. PLEASE DON’T BE IN SUCH A RUSH TO TO GO AND GET THESE MEDICATIONS THAT AREN’T TESTED, THAT AREN’T TREATED FROM AN UNTRUSTED SOURCE AS WELL. EARLIER THIS YEAR, THE FDA ISSUED WARNINGS TO TWO COMPANIES MAKING COMPOUNDED VERSIONS OF THESE DRUGS. WELL, THE AGENCY HAS ALSO RECEIVED AT LEAST 239 REPORTS OF ADVERSE REACTIONS TO COMPOUNDED SEMAGLUTIDE, BUT WARNED THAT NUMBER COULD BE HIGHER SINCE COMPOUNDING PHARMACIES ARE NOT
Advertisement
WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs
The World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines.WHO said Thursday that it has fielded several reports of fake semaglutide — the active ingredient in Novo Nordisk's Wegovy and Ozempic — in all geographic regions of the world since 2022.Related video above: Drugmaker warns of copy-cat weight loss medsLilly said in an open letter that it was "deeply concerned" about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.The Indianapolis-based company said it was the only lawful supplier of those drugs, and it does not provide tirzepatide to compounding pharmacies, wellness centers or online retailers.Lilly said fake versions of its drugs frequently advertised or sold online are never safe to use.Novo Nordisk has issued similar warnings in the past about its medications.WHO said patients can protect themselves by using prescriptions from licensed physicians to buy the medications. The agency said patients also should avoid buying the drugs from unfamiliar sources.Lilly said any products marketed as tirzepatide and not Mounjaro or Zepbound were not made by the drugmaker and are not approved by the U.S. Food and Drug Administration.

The World Health Organization and drugmaker Eli Lilly and Co. are warning people to be wary of fake versions of popular weight-loss and diabetes medicines.

Advertisement

WHO said Thursday that it has fielded several reports of fake semaglutide — the active ingredient in Novo Nordisk's Wegovy and Ozempic — in all geographic regions of the world since 2022.

Related video above: Drugmaker warns of copy-cat weight loss meds

Lilly said in an open letter that it was "deeply concerned" about growing online sales and social media posts involving phony or compounded versions of tirzepatide, the active ingredient behind its drugs Mounjaro and Zepbound.

The Indianapolis-based company said it was the only lawful supplier of those drugs, and it does not provide tirzepatide to compounding pharmacies, wellness centers or online retailers.

Lilly said fake versions of its drugs frequently advertised or sold online are never safe to use.

Novo Nordisk has issued similar warnings in the past about its medications.

WHO said patients can protect themselves by using prescriptions from licensed physicians to buy the medications. The agency said patients also should avoid buying the drugs from unfamiliar sources.

Lilly said any products marketed as tirzepatide and not Mounjaro or Zepbound were not made by the drugmaker and are not approved by the U.S. Food and Drug Administration.